Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid
Abstract Background Bisphosphonates have a high adsorption on calcified tissues and are commonly used in the treatment of bone disorder diseases. Conjugates of bisphosphonates with macrocyclic chelators open new possibilities in bone targeted radionuclide imaging and therapy. Subsequent to positron...
Main Authors: | M. Meckel, R. Bergmann, M. Miederer, F. Roesch |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2016-09-01
|
Series: | EJNMMI Radiopharmacy and Chemistry |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s41181-016-0017-1 |
Similar Items
-
[177Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results
by: Madhav Prasad Yadav, et al.
Published: (2020-10-01) -
Labeling of DOTA-conjugated HPMA-based polymers with trivalent metallic radionuclides for molecular imaging
by: Elisabeth Eppard, et al.
Published: (2018-02-01) -
Preparation and Preliminary Evaluation of Neurotensin Radiolabelled with <sup>68</sup>Ga and <sup>177</sup>Lu as Potential Theranostic Agent for Colon Cancer
by: Radu Anton Leonte, et al.
Published: (2021-04-01) -
Preparation, Characterization, and Radiolabeling of [<sup>68</sup>Ga]Ga-NODAGA-Pamidronic Acid: A Potential PET Bone Imaging Agent
by: Zarif Ashhar, et al.
Published: (2020-06-01) -
Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab′)2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab′)2 – implications for a PET theranostic strategy
by: Anthony Ku, et al.
Published: (2021-08-01)